GlassScriptPhysician profile
Sonia Chadha
NPI 1952341711
$4,287.22
in general payments reported to CMS, 2019-2025
36 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $190 · 2021: $478 · 2022: $750 · 2023: $864 · 2024: $613 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,601.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $451.03 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $380.77 | 2023-2025 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $311.52 | 2022 | |
| Abiomed | $304.63 | 2023-2024 | Impella |
| Lilly USA, LLC | $301.84 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $278.37 | 2019-2023 | Xarelto |
| Bausch Health US, LLC | $268.95 | 2021-2025 | Wellbutrin, Aplenzin |
| Novo Nordisk INC | $254.55 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $241.77 | 2019-2025 | |
| Esperion Therapeutics, INC. | $215.56 | 2020-2022 | |
| Insmed, INC. | $149.42 | 2025 | Brinsupri |
| Qapel Medical INC | $147.26 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $145.56 | 2019-2024 | Airsupra |
| Abbvie INC. | $141.53 | 2022 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $71.63 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $55.94 | 2020-2022 | |
| Boston Scientific Corporation | $49.19 | 2020-2025 | Watchman Access System |
| Amgen INC. | $43.51 | 2021-2023 | Prolia, Evenity |
| Amarin Pharma, INC. | $42.77 | 2021 | |
| Dynavax Technologies Corporation | $29.92 | 2024 | Heplisav-B |
| Sun Pharmaceutical Industries INC. | $28.93 | 2021 | |
| Hikma Pharmaceuticals USA | $27.16 | 2021-2024 | Ryaltris |
| Pharmacosmos Therapeutics INC. | $24.66 | 2025 | Monoferric |
| Itamar Medical INC | $23.88 | 2022 | |
| Corcept Therapeutics | $22.81 | 2025 | Korlym |
| Renalytix Ai, INC. | $19.50 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Bavarian Nordic A/S | $17.29 | 2025 | Vaxchora, Vivotif |
| Braeburn INC. | $16.78 | 2025 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $16.63 | 2023 | Nuedexta |
| Insightec,INC | $13.92 | 2025 | Exablate |
| Acadia Pharmaceuticals INC | $13.85 | 2023 | Nuplazid |
| Gilead Sciences, INC. | $13.64 | 2023 | |
| Merck Sharp & Dohme LLC | $13.62 | 2022 | |
| Eyevance Pharmaceuticals LLC | $12.95 | 2021 | |
| Cequr Corporation | $10.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Chadha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.